Short Interest in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Rises By 56.3%

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 13,600 shares, an increase of 56.3% from the October 15th total of 8,700 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average trading volume of 14,500 shares, the short-interest ratio is currently 0.9 days.

Cryo-Cell International Stock Performance

Shares of NYSEAMERICAN CCEL opened at $8.43 on Friday. The stock has a market capitalization of $67.95 million, a price-to-earnings ratio of -7.95 and a beta of 0.43. Cryo-Cell International has a twelve month low of $3.67 and a twelve month high of $9.50.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.11. Cryo-Cell International had a negative return on equity of 42.06% and a negative net margin of 28.03%. The company had revenue of $8.07 million for the quarter.

Cryo-Cell International Dividend Announcement

The company also recently declared a — dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Friday, November 15th.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Geode Capital Management LLC raised its stake in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) by 68.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,860 shares of the company’s stock after buying an additional 16,203 shares during the quarter. Geode Capital Management LLC owned about 0.49% of Cryo-Cell International worth $254,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.